Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
TAPENTADOL vs ACETAMINOPHEN AND CODEINE PHOSPHATE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Tapentadol is a centrally acting analgesic with a dual mechanism of action: mu-opioid receptor agonist and norepinephrine reuptake inhibitor.
Acetaminophen: centrally acting analgesic and antipyretic, possibly via inhibition of cyclooxygenase (COX) and modulation of cannabinoid receptors. Codeine: prodrug converted to morphine; mu-opioid receptor agonist.
Management of moderate to severe acute pain,Management of neuropathic pain associated with diabetic peripheral neuropathy,Management of chronic pain
Mild to moderate pain,Pain accompanied by fever
Immediate-release tablets: 50-100 mg orally every 4-6 hours as needed for pain; maximum 600 mg per day. Extended-release tablets: 50-250 mg orally twice daily (every 12 hours); maximum 500 mg per day.
One or two tablets (acetaminophen 300 mg/codeine 30 mg per tablet) orally every 4-6 hours as needed for pain; maximum 12 tablets daily.
Terminal elimination half-life is approximately 4 hours (range 3-5 hours) for immediate-release; for extended-release, effective half-life is about 4-6 hours due to prolonged absorption.
Acetaminophen: 2–3 hours (prolonged in hepatic impairment). Codeine: 2.5–3.5 hours; metabolites: morphine 1.5–2.5 hours, codeine-6-glucuronide 3–4 hours. Clinical context: dosing interval every 4–6 hours.
Extensively metabolized via conjugation (primarily glucuronidation) and by CYP2C9 and CYP2C19 to a minor extent. Major metabolites are inactive.
Acetaminophen: primarily glucuronidation and sulfation in liver; minor CYP450 (CYP2E1) to toxic NAPQI. Codeine: CYP2D6 to morphine; CYP3A4 to norcodeine; glucuronidation.
Primarily renal: approximately 95% of the dose is excreted in urine (60% as tapentadol glucuronide, 15% as unchanged tapentadol, and 20% as other metabolites); less than 3% excreted in feces.
Acetaminophen: renal elimination of conjugated metabolites (glucuronide 60%, sulfate 30%, cysteine/mercapturate <5%), less than 5% unchanged. Codeine: renal elimination of codeine (5–15%), morphine (5–10%), norcodeine (10–20%), and conjugates; 90% excreted in urine within 24 hours.
Approximately 20% bound to plasma proteins (primarily albumin).
Acetaminophen: 10–25% (albumin). Codeine: 7–25% (primarily albumin).
540 L (approximately 7.7 L/kg for a 70 kg adult), indicating extensive tissue distribution.
Acetaminophen: 0.9 L/kg. Codeine: 3–6 L/kg (extensive tissue distribution).
Oral: approximately 32% due to first-pass metabolism; intravenous: 100%.
Oral: acetaminophen 88% (variable first-pass); codeine 50–60% (first-pass metabolism to morphine, norcodeine, and conjugates).
Creatinine clearance (Cr Cl) 30-80 m L/min: No adjustment needed. Cr Cl <30 m L/min: Not recommended (extended-release) or use with caution and reduce dose by 50% (immediate-release). Hemodialysis: Not recommended.
GFR 30-50 m L/min: administer every 6 hours; GFR 10-29 m L/min: administer every 8 hours; GFR <10 m L/min: administer every 12 hours; hemodialysis: not recommended.
Child-Pugh Class A: No adjustment. Child-Pugh Class B: Reduce dose by 50% and increase dosing interval to every 8 hours (immediate-release) or every 12 hours (extended-release). Child-Pugh Class C: Contraindicated.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50% and extend interval to every 8 hours; Child-Pugh C: contraindicated.
Safety and efficacy not established in children <18 years; not recommended.
For children ≥12 years: acetaminophen 10-15 mg/kg/dose and codeine 0.5-1 mg/kg/dose orally every 4-6 hours; maximum acetaminophen 75 mg/kg/day, codeine 6 mg/kg/day. For children <12 years: not recommended due to codeine safety concerns.
Start at low end of dosing range; monitor for CNS effects, constipation, and respiratory depression. Immediate-release: 50 mg every 6 hours initially; extended-release: not recommended for opioid-naïve elderly.
Start with lowest effective dose; acetaminophen component maximum 3 g/day; consider reduced codeine dose (e.g., 15 mg) due to increased sensitivity and risk of respiratory depression; extend dosing interval to every 6-8 hours.
Risk of addiction, abuse, and misuse; life-threatening respiratory depression; accidental ingestion; neonatal opioid withdrawal syndrome; risks from concomitant use with benzodiazepines or other CNS depressants; and interactions with drugs affecting cytochrome P450 isoenzymes.
Risk of medication errors: confusion between milligram and milliliter doses, and between codeine and acetaminophen components. Contraindicated for postoperative pain management in children following tonsillectomy/adenoidectomy due to risk of respiratory depression and death.
Addiction, abuse, and misuse; life-threatening respiratory depression; neonatal opioid withdrawal syndrome; risks from concomitant use with benzodiazepines or other CNS depressants; severe hypotension; seizures; risk of serotonin syndrome; adrenal insufficiency; and withdrawal.
Hepatotoxicity (acetaminophen overdose); respiratory depression; drug dependence; ultra-rapid metabolizers of codeine (CYP2D6) leading to morphine toxicity; concomitant CNS depressants; use in pediatric patients; avoid alcohol.
Significant respiratory depression; acute or severe bronchial asthma in an unmonitored setting or in absence of resuscitative equipment; known or suspected gastrointestinal obstruction; concurrent use of MAOIs or within 14 days; hypersensitivity to tapentadol.
Hypersensitivity to acetaminophen or codeine; severe respiratory depression; acute or severe asthma; paralytic ileus; post-operative pain management in children after tonsillectomy/adenoidectomy; breastfeeding (in ultra-rapid metabolizers); concomitant MAOIs.
No specific food interactions. Alcohol should be avoided due to additive CNS depressant effects.
Avoid alcohol; high-fat meals may delay absorption but not clinically significant.
First trimester: Limited data, no clear evidence of major malformations in humans, but opioid use associated with neural tube defects in some studies. Second and third trimesters: Chronic use may lead to fetal opioid dependence and neonatal opioid withdrawal syndrome (NOWS). Avoid prolonged use near term due to risk of respiratory depression at birth.
Acetaminophen is considered low risk in all trimesters at therapeutic doses; chronic high doses may be associated with adverse outcomes. Codeine is associated with risk of respiratory depression and neonatal withdrawal if used near term; may cause neural tube defects and other malformations with first-trimester exposure, but data are conflicting. Use lowest effective dose for shortest duration.
Excreted into breast milk in low concentrations (M/P ratio approximately 0.8). Infant exposure is low but may cause sedation or respiratory depression in neonates, especially with high maternal doses or prolonged use. Caution advised; monitor infant for signs of sedation or poor feeding.
Acetaminophen is excreted into breast milk in low amounts (M/P ratio ~0.91-1.42) and is considered compatible with breastfeeding. Codeine is also excreted in breast milk; risk of infant opioid toxicity depends on maternal CYP2D6 phenotype. Ultra-rapid metabolizers may produce higher morphine levels. Use with caution, avoid in known CYP2D6 ultra-rapid metabolizers, and monitor infant for sedation and respiratory depression.
No specific dose adjustments recommended, but pharmacokinetic changes in pregnancy (increased clearance, volume of distribution) may require higher doses to maintain analgesia. Use lowest effective dose for shortest duration. Avoid chronic use; consider opioid-sparing strategies.
No routine dose adjustment needed for acetaminophen. Codeine pharmacokinetics are altered in pregnancy: increased clearance and volume of distribution may require dose adjustment; however, due to variability in CYP2D6 metabolism, individualize dosing and monitor for efficacy and toxicity. Avoid codeine in pregnancy unless alternative analgesics are ineffective.
Tapentadol is a dual-mechanism opioid agonist and norepinephrine reuptake inhibitor. It has a lower incidence of opioid-induced nausea and vomiting compared to morphine. Avoid use in patients with severe hepatic impairment. Maximum daily dose is 600 mg. Do not crush extended-release tablets. Discontinuation should be gradual to avoid withdrawal. Serotonin syndrome risk when combined with serotonergic agents.
For acute pain, limit codeine to 3 days; avoid in children under 12 due to CYP2D6 ultra-rapid metabolizer risk of fatal respiratory depression; monitor for constipation; assess liver function for acetaminophen hepatotoxicity; use with caution in renal impairment.
Take exactly as prescribed; do not increase dose or frequency without consulting your doctor.,Do not crush, chew, or dissolve tablets; swallow whole.,Avoid alcohol and other CNS depressants (e.g., sedatives, tranquilizers) as they may increase risk of serious side effects like respiratory depression.,Dizziness or drowsiness may occur; avoid driving or operating machinery until you know how the medication affects you.,Do not stop abruptly; taper dose under medical supervision to prevent withdrawal symptoms.,Common side effects include nausea, vomiting, constipation, dizziness, and headache.,Report symptoms of serotonin syndrome (e.g., agitation, hallucinations, rapid heartbeat, fever, muscle stiffness) immediately.,Keep out of reach of children; misuse can cause overdose and death.
Take exactly as prescribed; do not exceed 4000 mg acetaminophen per day.,Avoid alcohol while taking this medication.,Do not use with other acetaminophen-containing products.,May cause dizziness or drowsiness; avoid driving until you know how you react.,Common side effects include constipation, nausea, and drowsiness.,Seek emergency if signs of allergic reaction or difficulty breathing occur.
"The combination of Propiverine, an anticholinergic agent used for overactive bladder, with Tapentadol, a mu-opioid receptor agonist and norepinephrine reuptake inhibitor, can result in additive anticholinergic effects. This increases the risk of severe adverse effects such as urinary retention, constipation, dry mouth, blurred vision, and central nervous system depression. Elderly patients are especially susceptible to these effects, which may lead to falls, cognitive impairment, or anticholinergic toxicity."
"Lorazepam, a benzodiazepine, potentiates the central nervous system (CNS) depressant effects of tapentadol, an opioid analgesic, by enhancing GABAergic activity and reducing neurotransmitter release. This additive pharmacodynamic interaction can lead to excessive sedation, respiratory depression, profound hypotension, and increased risk of coma or death, particularly in elderly or debilitated patients. Clinical outcomes include heightened CNS depression, impaired psychomotor function, and potential for opioid-induced respiratory compromise when used concomitantly."
"Zonisamide, a sulfonamide anticonvulsant, potentiates the central nervous system (CNS) depressant effects of tapentadol, a mu-opioid agonist and norepinephrine reuptake inhibitor. This additive pharmacodynamic interaction can lead to excessive sedation, respiratory depression, and impaired psychomotor function, particularly when initiating or titrating either drug. Patients may experience increased risk of falls, cognitive impairment, and potentially life-threatening respiratory compromise."
"Pirenzepine, a selective M1 muscarinic antagonist, reduces gastrointestinal motility and secretions, while codeine, an opioid agonist, also decreases gastrointestinal motility via mu-opioid receptors. Concurrent use leads to additive anticholinergic and opioid effects, resulting in enhanced risk of severe constipation, paralytic ileus, and central nervous system depression. Clinically, patients may experience exacerbated sedation, respiratory depression, and urinary retention."
"Ropinirole, a non-ergoline dopamine agonist used in Parkinson's disease and restless legs syndrome, may reduce the analgesic efficacy of codeine. This is likely due to pharmacodynamic antagonism at central dopamine and opioid receptors, as well as potential pharmacokinetic interactions that decrease the conversion of codeine to its active metabolite morphine via CYP2D6 inhibition by ropinirole. The resultant blunted opioid response can lead to inadequate pain control, necessitating dose adjustment or alternative therapy."
"Vemurafenib induces CYP3A4, significantly reducing the plasma concentrations of codeine, which is metabolized via CYP3A4 to its active metabolite morphine. This may diminish codeine's analgesic efficacy, potentially leading to inadequate pain control. Additionally, reduced formation of morphine may lower the risk of opioid-related adverse effects."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about TAPENTADOL vs ACETAMINOPHEN AND CODEINE PHOSPHATE, answered by our medical review team.
TAPENTADOL is a Opioid Agonist that works by Tapentadol is a centrally acting analgesic with a dual mechanism of action: mu-opioid receptor agonist and norepinephrine reuptake inhibitor.. ACETAMINOPHEN AND CODEINE PHOSPHATE is a Opioid Agonist that works by Acetaminophen: centrally acting analgesic and antipyretic, possibly via inhibition of cyclooxygenase (COX) and modulation of cannabinoid receptors. Codeine: prodrug converted to morphine; mu-opioid receptor agonist.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between TAPENTADOL and ACETAMINOPHEN AND CODEINE PHOSPHATE depend on the specific clinical indication. These are both Opioid Agonist agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of TAPENTADOL is: Immediate-release tablets: 50-100 mg orally every 4-6 hours as needed for pain; maximum 600 mg per day. Extended-release tablets: 50-250 mg orally twice daily (every 12 hours); maximum 500 mg per day.. The standard adult dose of ACETAMINOPHEN AND CODEINE PHOSPHATE is: One or two tablets (acetaminophen 300 mg/codeine 30 mg per tablet) orally every 4-6 hours as needed for pain; maximum 12 tablets daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
A moderate-severity drug interaction has been identified when combining TAPENTADOL and ACETAMINOPHEN AND CODEINE PHOSPHATE. Concurrent use of codeine and tapentadol results in additive central nervous system (CNS) depression, leading to increased risks of respiratory depression, sedation, coma, and death. Both drugs are mu-opioid receptor agonists, and tapentadol additionally inhibits norepinephrine reuptake, which does not mitigate the additive CNS effects. This combination should be avoided unless benefits outweigh risks, and patients must be closely monitored for signs of excessive CNS depression. Consult your prescriber before combining these medications.
The maternal-fetal safety profiles differ. TAPENTADOL is classified as Category A/B. First trimester: Limited data, no clear evidence of major malformations in humans, but opioid use associated with neural tube defects in some studies. Second and third trimesters: . ACETAMINOPHEN AND CODEINE PHOSPHATE is classified as Category D/X. Acetaminophen is considered low risk in all trimesters at therapeutic doses; chronic high doses may be associated with adverse outcomes. Codeine is associated with risk of respirat. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.